



Business Update & Progress Report

Australia's leading manufacturer & wholesaler of novel medicines

ASX:BXN

Important Notice and Disclaimer



This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, Bioxyne does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain “forward-looking statements”. The words “forecast”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and uncertainties and other factors which are beyond the control of Bioxyne, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to Bioxyne as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of Bioxyne, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than Bioxyne has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, Bioxyne (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in Bioxyne or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire Bioxyne securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of Bioxyne and the impact that different future outcomes may have on Bioxyne. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Bioxyne is not licensed to provide financial product advice in respect of its securities or any other financial products.

Presentation Guide

1. Australian Operations Performance

2. European Progress

3. UK Progress

4. MDMA Medicines Development

5. FY2025 Revenue Guidance





Australian Operations Update FY25



Australia's Leading Medical Cannabis Manufacturer



**BXN has outperformed its growth forecasts over the last 12 months.
In 2024 our goal was to become the leading medical cannabis manufacturer.
Here are the results:**

>1 million

Finished medicines
manufactured

~15 million

individual pastilles in the last
12 months

>12,000 KG

of Cannabis Flower GMP
Packed

>400m²

Of Controlled Drug Storage

>110,000

Finished products per
month

600,000

Daily pastille capacity
increased to...

~15%

Of Australia's Medical
Cannabis Flower

>300m²

Clean Room Manufacturing
space

We work with 100+ companies in Australia



~100

B2B Clients

~\$280k

Avg. Annual Order Value

\$3m

Current run rate, sales/month

3

Sales Team Headcount (Aus)

40

Operations Team Headcount (Aus) –
50% flexible contract



~\$1,000,000

Annual Sales

33

Australian SKUs

18

UK Registered

16

Germany Registered

European Progress Report

Shareholder Presentation | June 2025

Selling Tons to Europe

European Cannabis is a 200+ tons per year market opportunity

Germany

16

BfArM Product Registrations
Submitted

>140 TONS

Cannabis Flower Market per
Year

Czechia

\$500,000

Investment in EUGMP Flower
Packing facility planned in
FY26

Other EU Markets

Malta

Fcst Revenue from finished
products (inc. pastilles)

\$5.6m

Contracted minimum
revenue for FY2026 (one
client)

EU GMP

BLS is now certified EU GMP
compliant under MRA

20 Tons

Target Annual Flower Packing
Capacity

Poland

~30 Tons / year

Revenue streams:

1. Sale of bulk GMP Flower (Manufactured by BLS) to importers / distributors / manufacturers
2. Sale of DR Watson branded Product to Pharmacy via Importers / distributors



UK Progress Report

Shareholder Presentation | June 2025

Bioxyne

The UK is a sleeping giant

Pastilles, Flower, Oils, Vape, Pessaries, Suppositories

Pricing and quality arbitrage and limited local manufacturing automation or scale...

~80,000

Estimated medical cannabis patients in the UK in 2025

4 x

Import and distribution partners in the UK Signed

18 +

BLS CBPMs registered with the Home Office & MHRA

~A\$2.5m

Value of first shipment of CBPMs to UK from Aus. @sale value to clinics

2,000,000

Regular (monthly) cannabis users¹

10 x

Finalizing commercial terms with 10 UK clinics & pharmacies representing 60,000 patients

Pastilles

Are a significant opportunity for BXN in the UK

\$2Bn/year

Annual market fcst by 2030

Revenue streams:

1. Sale of bulk GMP Flower (Manufactured by BLS) to importers / distributors / manufacturers
2. Sale of DR Watson branded Product to Pharmacy via Importers / distributors
3. Sale of White label products made in Australia as intermediate for label and release in UK

1. <https://publications.parliament.uk/pa/ld199798/ldselect/ldsctech/151/15108.htm>



Psychedelics Progress Update



Development of BLSMD40 and BLSMD100 MDMA Capsules Complete & Commercially Ready



BLSMD40 and BLSMD100 Capsules contain 40mg and 100mg of 3,4-Methylenedioxymethamphetamine Hydrochloride.

50g MDMA

Imported in 2025

500–1,250

Patient Doses

10kg + 10g

Psilocybe Cubensis Fungi +
Synthetic Psilocybin API
Imported in 2025

5000+

Patient Doses

July 2025

First Revenues

R&D

Continues through 2025
CY



Revenue Guidance for FY25 (June)



FY25 Revenue Upgrade

Target: Continued growth and maintaining profitability metrics

\$25m

Previous Guidance

\$28m

Revised Guidance

~50%

FCST Gross Margin*

**Profitable
&
Cashflow Positive for
the Full Year**

* 50% before sales commissions

Bioxyne revenues from operations (\$'000's)

